Distinct compositional alterations in plasma lipoproteins in type 2 diabetes: a cross-sectional study of healthy individuals and diabetics with and without cardiovascular comorbidities
Authors' conclusion
T2DM is associated with major alterations in LP metabolism independent of hypertension or CVD. Thus, early lipid management in T2DM is important to mitigate CVD risk. Further research is needed to elucidate how T2DM progresses to CVD in relation to atherogenic LPs.
Study context
- Population
- Healthy individuals and patients with T2D with and without cardiovascular comorbidities; 65 lipoprotein parameters quantified65 LP parameters
- Exposure
- T2D patients with and without cardiovascular comorbidities vs healthy controls
- Outcome
- Lipoprotein profile, T2DM vs HC
Methodological details1H NMR spectroscopy lipoprotein profiling, univariate and multivariate analyses
- 1H NMR spectroscopy lipoprotein profiling
- Univariate and multivariate analyses
Main finding
As reported in the abstract
- Triglycerides in all major LP classes increased in T2DM vs healthy controls (HC)
- Very low-density lipoproteins (VLDL) and intermediate-density lipoproteins (IDL) particle numbers increased in T2DM vs HC
- Low-density lipoproteins (LDL) and high-density lipoproteins (HDL) particle numbers reduced in T2DM vs HC
- Univariate and multivariate analyses converged in identifying distinct LP profiles associated with T2DM
Observational data: associations, not effects.
Further findings
Hypertension or cardiovascular disease (CVD) within T2DM
- Differences between patients with and without hypertension or CVD were minor
- T2DM, with or without cardiovascular comorbidities, causes differential disruption of the correlation structure among lipoproteins (LPs)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Distinct compositional alterations in plasma lipoproteins in type 2 diabetes: a cross-sectional study of healthy individuals and diabetics with and without cardiovascular comorbidities. Cardiovasc Diabetol. Published 25 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →